* Survivor / Patient forum * Donations * Memberships * Corporate Partners * Oral cancer in the news * Oral cancer facts * Diagnosis * Treatment * Restoration / Rehabilitation * Dental Issues * Emotional aspects * OCF in the news * Oral cancer events * The Tobacco Connection * The HPV Connection * People * Store * Products * Other Resources * Grants / Jobs * Research / Clinical trials * Multimedia * Volunteer to Help * Media/Press Kit * About us * Newsletter * Search * Site Map Matched Analysis of Survival in Patients With SCC Diagnosed Before and After 40 Years of Age
7/18/2004 Houston, TX See below for authors Arch Otolaryngol Head Neck Surg. 2004;130:869-873. Objectives : To compare the survival rates of patients 40 years or younger and diagnosed with squamous cell carcinoma of the head and neck (SCCHN) with those of patients older than 40 years who underwent the same treatment. In 2 previous matched-pair analyses, the patients had been matched for tumor stage, site, sex, and date of presentation but not type of treatment. Methods: Between 1995 and 2001, 46 patients 40 years or younger participated in a prospective epidemiologic study that included more than 500 patients newly diagnosed with SCCHN. We matched each of these patients by sex, race, tumor site, overall stage, and treatment modality with 2 patients older than 40 years. Ultimately, 31 of the younger patients were matched with 62 of the older patients. Survival analysis was performed using Cox proportional hazard models and accounting for the matched trios. Results: There was no difference in overall, disease-specific, or recurrence-free survival rates between the patients who were 40 years or younger and those older than 40 years. Furthermore, matched survival analysis did not demonstrate a difference in overall survival rate (risk ratio [RR], 0.71; 95% confidence interval [CI], 0.22-2.29; P = .56), disease-free survival rate (RR, 0.83; 95% CI, 0.20-3.33; P = .79), or time to recurrence (RR, 1.46; 95% CI, 0.50-4.23; P = .49), and was not affected by adjustment for medical comorbidities or the severity of cancer-associated symptoms. Conclusions: We found no evidence of a difference [...]